sulfinpyrazone has been researched along with Arteriosclerosis Obliterans in 1 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Arteriosclerosis Obliterans: Common occlusive arterial disease which is caused by ATHEROSCLEROSIS. It is characterized by lesions in the innermost layer (ARTERIAL INTIMA) of arteries including the AORTA and its branches to the extremities. Risk factors include smoking, HYPERLIPIDEMIA, and HYPERTENSION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zabel Langhennig, R | 1 |
1 other study available for sulfinpyrazone and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
[Inhibitors of platelet aggregation in the therapy of arteriosclerosis obliterans].
Topics: Arteriosclerosis Obliterans; Aspirin; Diabetic Angiopathies; Dipyridamole; Humans; Platelet Aggregat | 1979 |